Dose expansion data from iintune-1, a phase 1/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN).
Bibliographic record
Abstract
6020 Background: Checkpoint inhibitors (CPIs) such as pembrolizumab (pembro) can lead to improved outcomes and durable responses in patients (pts) with RM-SCCHN. However, only a subset of pts with RM-SCCHN experience this benefit, and an unmet need for better treatments remains. STimulator of INterferon Genes (STING) agonism enhanced the response to CPIs preclinically. Dazostinag (dazo) is a small molecule STING agonist that has shown antitumor activity and activation of innate and adaptive immune responses in pts with solid tumors in the dose escalation part of iintune-1, with a recommended dose for expansion of 5 mg in combination with pembro. We report data from the ongoing dose expansion cohort 2A of iintune-1 in the first 30 pts with incurable 1L RM-SCCHN with a PD-L1 combined positive score (CPS) ≥1, treated with dazo in combination with pembro (NCT04420884). Methods: Pts receive dazo 5 mg IV on Days 1, 8, 15 plus pembro 200 mg IV on Day 1, in 21-day cycles. Primary endpoints are safety and tolerability. Secondary endpoints include investigator-assessed overall response rate (ORR) per RECIST 1.1 and duration of response (DOR). Dose optimization is planned as part of expansion. Results: As of Dec 16, 2024, 30 pts had been enrolled and received treatment. Median age was 64 years and 73% of pts were male. The most common primary tumor locations were oral cavity (n=10, 33%), oropharynx (n=8, 27%), and larynx (n=6, 20%). Median CPS score was 13.5 (range, 1–101). A median of 4.5 treatment cycles (range 1–15) were received. Treatment-emergent adverse events (TEAEs) occurred in all pts (grade ≥3 in 37%); the most common were fatigue (40%), nausea (27%), cough (23%), and headache (20%). Dazo-related TEAEs occurred in 80% of pts (grade ≥3 in 13%); the most common was fatigue (30%). Cytokine release syndrome was reported in 4 pts (13%; all dazo-related and grade 1–2). TEAEs led to dazo discontinuation in 1 pt. No treatment-related deaths were reported. Among 29 response-evaluable pts, 1 had a confirmed complete response and 7 had confirmed partial responses (+2 unconfirmed), for an ORR of 34%. Median DOR was not reached. Pharmacodynamic analyses revealed biomarker changes consistent with the expected mechanism of action and dose escalation data, including induction of a STING gene signature, cytokine induction, peripheral immune cell activation and CD8+ T cell recruitment to the tumor. Analyses of changes in peripheral ctDNA pre- and post-treatment are ongoing. Conclusions: This early study of dazo 5 mg IV in combination with pembro showed a manageable safety profile with an encouraging ORR in pts with RM-SCCHN. Pharmacodynamic findings demonstrate peripheral and intratumor changes consistent with STING agonism. Clinical trial information: NCT04420884 .
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".